Skip to main content

Table 1 Demographic, clinical and laboratory characteristics of patients in each outcome group

From: DKK1 expression by synovial fibroblasts in very early rheumatoid arthritis associates with lymphocyte adhesion in an in vitro flow co-culture system

 

Resolving arthritis (n = 11)

VeRA (n = 14)

p Value

Age, yr

37.4 ± 10.3

52.9 ± 9.5

0.001

Female, n (%)

3 (27.3)

9 (64.3)

<0.0001

Disease duration, wk

4.4 ± 2.9

6.1 ± 3.3

0.210

CCP-positive, n (%)

0 (0)

7 (50)

<0.0001

RF-positive, n (%)

0 (0)

6 (42.9)

<0.0001

TJC28

2.6 ± 2.0

7.9 ± 5.8

0.008

SJC28

2.7 ± 2.0

7.3 ± 5.3

0.011

CRP

8.4 ± 8.1

23.0 ± 27.0

0.097

ESR

16.4 ± 15.5

31.1 ± 22.4

0.075

VAS

42.3 ± 32.1

46.9 ± 28.1

0.703

DAS28-ESR

3.5 ± 1.0

4.9 ± 1.2

0.004

Radiographic erosions, n (%)

0 (0)

1 (7.1)

<0.0001

  1. VeRA very early rheumatoid arthritis, CCP cyclic citrullinated peptide, RF rheumatoid factor, TJC28 28-joint tender joint count, SJC28 28-joint swollen joint count, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28-ESR Disease Activity Score in 28 joints based on erythrocyte sedimentation rate, VAS visual analogue scale
  2. Data are presented as mean ± standard deviation unless otherwise indicated